John K. Scott Jr. - Aug 30, 2022 Form 4 Insider Report for NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB)

Role
Director, 10%+ Owner
Signature
/s/ Erika L. Eves for John K. Scott, Jr. by power of attorney
Stock symbol
NAVB
Transactions as of
Aug 30, 2022
Transactions value $
-$2,399,999
Form type
4
Date filed
9/1/2022, 09:45 PM
Previous filing
Aug 1, 2022
Next filing
Oct 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAVB Common Stock Award $0 +2.5K +0.03% $0.00 8.1M Aug 31, 2022 Direct F1, F2
holding NAVB Common Stock 10.1K Aug 30, 2022 By spouse and children F3
holding NAVB Series G Redeemable Preferred Stock 3.26K Aug 30, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAVB Series F Redeemable Convertible Preferred Stock Sale -$2.4M -1.74K -100% $1,379.31* 0 Aug 30, 2022 Common Stock 2.18M $0.80 Direct F4, F5
transaction NAVB Series I Convertible Preferred Stock Purchase +2.4K 2.4K Aug 30, 2022 Common Stock 5.33M $0.45 Direct F6, F7
transaction NAVB Warrant to Purchase Common Stock Purchase +2.4K 2.4K Aug 30, 2022 Common Stock 5.33M $0.50 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of monthly non-employee director fees.
F2 Issuance deferred at the request of the Reporting Person.
F3 Includes 2,639 shares of Common Stock owned by the Reporting Person's spouse and 7,500 shares of Common Stock owned by the Reporting Person's children. The Reporting Person may be deemed to have shared voting and/or dispositive power with respect to such shares.
F4 Series F Redeemable Convertible Preferred Stock, par value $.001 per share, was surrendered to pay the subscription price for the units purchased in the Rights Offering. The fair market value of the Series F Redeemable Convertible Preferred Stock surrendered in the Rights Offering was determined by the Issuer's board of directors based on an independent appraisal obtained by the Issuer.
F5 Series F Redeemable Convertible Preferred Stock, par value $.001 per share, was convertible at any time and had no expiration date.
F6 The Reporting Person acquired the Series I Convertible Preferred Stock and Warrants to Purchase Common Stock pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering ("Rights Offering"), as disclosed in the Registration Statement on Form S-1, as amended, and Prospectus Supplement No. 1 filed by the Issuer with the Securities and Exchange Commission. Pursuant to the Rights Offering, the Reporting Person purchased units at a subscription price of $1,000 per unit, with each unit consisting of one (1) share of Series I Convertible Preferred Stock and one (1) Warrant to Purchase 2,222 shares of Common Stock.
F7 Series I Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date.